I listened to the call and the only reason that I can conclude, thatmay have brought the share price down, is that some people may have thought that there would be a huge pop to the upside nearterm.
I took away from this conference call that positive things will take place going forward. There was no negativity. They will meet the previously forecast numbers. They are making progress on all fronts. Xifaxin is in trials for several indications, some of which, when approval comes will, IMHO, send this much, much higher. They are capturing a nice portion of the bowel preparation market and that will continue to gain more ground. Most of all, their original strategy to become the leader in the Gastro Pharma arena is going forward well. They are working on all of the drugs to improve the numbers, etc. They are always seeking out even more and the added expense in R&D, will decline as they move forward. I do not see a negative, that would cause the decline in price.
IMHO, if they achieve the goal, which, of course, will not happen tomorrow, but in the not all that distant future, this should prove to be a solid, upwardly targeted investment for the longs.
That's a whole lot of "IF's" to see this as a long term buy.
The market has it correct today in the sell off for a reason. To many open questions and you know how investors take a lack of skepticism in terms of pricing an equity ? Answer is you are seeing it today and will continue until SLXP comes out and gives definative guidance.
Not short, but just skeptical and can't see this as a long term buy right now
1) No control over expenses. 2) Meeting expectations is not what the street and investors want. 3) Guidance tepid at best from CC. 4) Barely met consensus estimates on Revenues. 5) With expenses running wild they will need to exceed Revenues by 30% in next quarter to meet consensus.
Look for SLXP to trade down over the next several weeks to a low of $10.75